Bioavailable Testosterone Rate-of-Change Interpretation

What Bioavailable Testosterone Actually Measures

Bioavailable testosterone captures the two fractions of testosterone that can enter target tissues and bind androgen receptors: the small free fraction (1 to 3% of total T) and the larger albumin-bound fraction (roughly 38 to 40%). The third fraction, tightly bound to SHBG, is biologically inert for most purposes.

This distinction matters because SHBG rises with age, caloric restriction, hyperthyroidism, hepatic disease, and exogenous estrogen use. A man with a total testosterone of 450 ng/dL but an SHBG of 70 nmol/L may have bioavailable testosterone well below 100 ng/dL, a level consistent with symptomatic hypogonadism despite a "normal" total T. Vermeulen A, et al.

How the Calculation Works

The most widely validated method is the Vermeulen equation, which uses total testosterone, SHBG (nmol/L), and a fixed albumin constant of 4.3 g/dL. Many labs perform equilibrium dialysis for free testosterone but estimate bioavailable testosterone mathematically from the same inputs. Direct immunoassay for free T is notoriously unreliable at low concentrations and is not recommended by the Endocrine Society.

Why BioT Outperforms Total T in Clinical Tracking

When you track a patient over years, total testosterone can stay stable while SHBG creeps upward, causing a silent decline in bioavailable testosterone. Rate-of-change analysis on total T alone misses this pattern entirely. Tracking BioT serially gives a more accurate picture of androgen bioactivity than any single metric.

Normal Reference Ranges for Bioavailable Testosterone

Reference ranges differ by sex, age, assay methodology, and the equation used. The numbers below are derived from population studies and major laboratory consortiums.

Men

| Age Group | BioT Reference Range (ng/dL) | |---|---| | 20 to 29 years | 131 to 682 | | 30 to 39 years | 120 to 520 | | 40 to 49 years | 95 to 430 | | 50 to 59 years | 80 to 360 | | 60 to 69 years | 68 to 310 | | 70 years and older | 50 to 250 |

These figures are consistent with the reference intervals published in the Endocrine Society's 2010 testosterone therapy guidelines and updated in their 2018 clinical practice guidance. Bhasin S, et al.

Most commercial labs (Quest Diagnostics, LabCorp) use a male adult range of approximately 83 to 257 ng/dL without age stratification, which can mask clinically meaningful decline in older men.

Women

Bioavailable testosterone in women ranges from approximately 0.6 to 5.0 ng/dL in premenopausal adults, dropping by roughly 50% between ages 20 and 45 even before menopause. Postmenopausal women not on hormone therapy typically measure 0.5 to 2.0 ng/dL. Davis SR, et al.

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019) states: "There is currently no validated assay suitable for clinical use in the assessment of testosterone levels in women," acknowledging that standard assays designed for male ranges lack the sensitivity needed at female physiologic levels. Davis SR, et al.

Optimal vs. Normal: Why the Distinction Matters

"Normal" is a statistical range derived from a population that includes many symptomatic, metabolically unhealthy individuals. "Optimal" refers to the range associated with best functional outcomes: body composition, bone density, cognitive performance, libido, and metabolic health.

Optimal Range in Men

Longevity medicine and testosterone replacement therapy literature consistently places optimal BioT in men between 130 and 280 ng/dL for symptom relief and metabolic benefit. The TRAVERSE trial (N=5,246), which assessed cardiovascular outcomes in men receiving testosterone replacement, enrolled participants with total testosterone below 300 ng/dL, a cutoff that corresponds to BioT in the range of 65 to 90 ng/dL depending on SHBG. Lincoff AM, et al.

Bone density data from the Testosterone Trials (TTrials, N=788 men aged 65 and older) showed significant improvement in volumetric bone mineral density in men whose total T was raised to the mid-normal range (approximately 400 to 500 ng/dL total T), suggesting BioT targets of 150 to 200 ng/dL for skeletal protection. Snyder PJ, et al.

Optimal Range in Women

For women receiving testosterone therapy for hypoactive sexual desire disorder (HSDD) or menopausal symptoms, the 2019 Global Consensus recommends targeting the upper quartile of premenopausal female norms, roughly 3.5 to 5.0 ng/dL BioT. Supraphysiologic levels correlate with acne, clitoral hypertrophy, and polycythemia. Davis SR, et al.

Rate-of-Change: The Core Interpretation Framework

A single BioT value is a photograph. A series of values is a film. Rate of change tells you whether you are on a trajectory toward deficiency, holding steady, or overcorrecting with therapy.

Calculating Your Personal Rate of Change

The simplest approach: express the difference between two measurements as a percentage of the earlier value, then divide by the interval in months.

Rate of change (% per month) = [(BioT at time 2 minus BioT at time 1) / BioT at time 1] x 100 / months elapsed

A healthy untreated man in his 40s losing approximately 1.5% per year will show a monthly rate of roughly minus 0.12% per month. A rate faster than minus 0.5% per month over six or more months warrants investigation for secondary causes: new SHBG-elevating medications, hepatic disease, thyroid dysfunction, or significant weight loss.

Clinically Actionable Thresholds

These thresholds are based on population decline data and clinical practice consensus:

| Rate of Change | Clinical Interpretation | |---|---| | Less than minus 1% per month (sustained 6+ months) | Accelerated decline. Evaluate for secondary cause. | | Minus 0.1% to minus 0.5% per month | Age-expected decline. Monitor annually. | | Minus 0.1% to plus 0.1% per month | Stable. Retest in 12 months if asymptomatic. | | Plus 0.5% to plus 2% per month (on TRT) | Therapeutic response. Confirm SHBG trend. | | Greater than plus 3% per month | Possible over-replacement or assay variability. Repeat fasting AM draw. |

Pre-Treatment Baseline Establishment

Before starting testosterone therapy, collect at minimum two BioT measurements at least four weeks apart, both drawn fasting in the morning between 7 and 10 AM. The Endocrine Society recommends confirming low testosterone with a second measurement before initiating therapy. Bhasin S, et al. A single low reading could reflect an acute illness, poor sleep the prior night, or a high-carbohydrate meal consumed before the draw.

Factors That Drive Rate-of-Change Acceleration

BioT can fall faster than expected age-related decline when specific conditions are present. Identifying the driver is more valuable than reacting to the number alone.

SHBG Elevation

SHBG is the most common cause of a widening gap between total T and bioavailable T. Conditions that raise SHBG include:

• Aging (SHBG rises approximately 1 to 2% per year after 50)
• Hyperthyroidism
• Primary biliary cirrhosis and other hepatic diseases
• Use of oral estrogens, anticonvulsants, and certain HIV antiretrovirals
• Significant caloric restriction or anorexia

A study in the Journal of Clinical Endocrinology and Metabolism (N=2,762 men, mean follow-up 9 years) found that SHBG increased by an average of 1.2 nmol/L per year after age 55, explaining a substantial portion of the decline in calculated free and bioavailable testosterone independent of changes in total T. Ferrini RL, Barrett-Connor E.

Obesity and Metabolic Syndrome

Body fat aromatizes testosterone to estradiol, suppressing LH release and lowering total T production. BioT drops even faster in obesity because adipose-derived estradiol also raises SHBG marginally while suppressing the hypothalamic-pituitary axis. Men with a BMI <30 who develop central obesity show accelerated BioT decline before changes appear in total T. Grossmann M.

Opioid-Induced Androgen Deficiency

Chronic opioid therapy suppresses GnRH pulsatility, causing hypogonadotropic hypogonadism. Patients on long-term opioids can lose 30 to 50% of BioT within weeks of therapy initiation. This rate of change is far steeper than any age-related decline and requires specific management distinct from primary hypogonadism. Daniell HW.

Interpreting BioT During Testosterone Replacement Therapy

Once TRT begins (injectable testosterone cypionate, transdermal gel, subcutaneous pellets, or nasal testosterone), the rate-of-change framework shifts entirely. You are no longer tracking natural decline but therapeutic response and titration accuracy.

Timing the Draw Relative to Dose

Draw timing relative to the last dose profoundly affects the measured BioT:

• Testosterone cypionate (weekly injection): draw at trough, 6 to 7 days post-injection, for the most conservative and reproducible reading.
• Daily transdermal gel: draw 2 to 4 hours after application for peak, or just before daily application for trough.
• Subcutaneous pellets: draw 4 to 6 weeks after insertion for peak, then at 3 months for mid-cycle.
• Nasal testosterone (Natesto): draw approximately 1 hour post-dose for a peak reading.

The AUA 2023 Testosterone Deficiency Guidelines specify: "Testosterone levels should be measured at steady state, which occurs 3 to 6 months after initiating therapy or changing dose." Measuring before steady state produces misleading rate-of-change calculations.

Target BioT on Therapy

Most experienced clinicians target BioT between 130 and 220 ng/dL in men on TRT, aiming to replicate mid-normal young adult physiology without supraphysiologic peaks. Persistent BioT above 280 ng/dL at trough should prompt dose reduction or interval extension to reduce the risk of polycythemia (hematocrit above 54%), which was observed in 7.5% of TRT-treated men in the TRAVERSE trial vs. 1.7% in placebo. Lincoff AM, et al.

Rate-of-Change Targets After Dose Adjustment

After a dose change, BioT should stabilize within one to two half-lives of the ester being used. Testosterone cypionate has a half-life of approximately 8 days. A 20 mg/week dose increase typically shifts trough BioT upward by 15 to 30 ng/dL within three to four weeks. If BioT rises more than 60 ng/dL per adjustment cycle, the dose increment was too large, increasing the risk of erythrocytosis and mood volatility.

Serial Monitoring Schedule: Practical Guide

Monitoring frequency depends on whether the patient is untreated, newly started on therapy, or stable.

Untreated Men and Women

• Baseline: two fasting AM draws, four weeks apart.
• Follow-up: annually if BioT is within optimal range and the patient is asymptomatic.
• Accelerated monitoring: every six months if BioT is 20 to 30% above the lower limit of their personal optimal range (early warning zone).

First 12 Months on TRT (Men)

• Week 6 after initiation: first on-therapy BioT plus hematocrit.
• Month 3: trough BioT, hematocrit, PSA, and a complete metabolic panel.
• Month 6: repeat full androgen panel.
• Month 12: full panel plus DEXA scan if baseline bone density was low.

The Endocrine Society recommends checking hematocrit at 3 and 6 months in the first year, then annually, reducing dose or donating blood if hematocrit exceeds 54%. Bhasin S, et al.

Stable Long-Term TRT

Once BioT has been within target range for two consecutive draws six months apart, annual monitoring is generally sufficient. Any symptomatic change (fatigue returning, libido drop, mood shift) should prompt an unscheduled draw.

Common Interpretation Errors

Comparing Values from Different Assays

BioT is calculated, not directly measured in most labs. Switching from one lab's equation to another mid-monitoring generates artificial rate-of-change signals. Always use the same laboratory and request the same calculation method (Vermeulen preferred) at every time point.

Using Afternoon or Post-Meal Draws

Total testosterone follows a circadian rhythm, peaking between 7 and 10 AM and declining by 20 to 35% by afternoon. A 2 PM draw after lunch can produce a BioT that appears 20 to 25% lower than the same patient's true morning peak, making the apparent rate of decline look far steeper than it is. Brambilla DJ, et al.

Ignoring Albumin When It Is Abnormal

The Vermeulen calculation assumes albumin at 4.3 g/dL. In patients with nephrotic syndrome, liver cirrhosis, or severe malnutrition, actual albumin may be 2.5 to 3.0 g/dL, falsely inflating the calculated albumin-bound fraction and thus overstating BioT. Request a measured albumin whenever a patient has any condition affecting protein synthesis.

Sex Hormone-Binding Globulin as a Co-Pilot Metric

Tracking SHBG alongside BioT converts a one-dimensional number into a two-dimensional story. SHBG explains why BioT changes, not just that it changed.

A patient whose BioT fell 15% over six months while total T stayed flat almost certainly shows a rising SHBG. Identifying that SHBG rose from 45 to 62 nmol/L during that interval points toward a cause: new thyroid medication, weight loss, or subclinical liver disease. The treatment then targets the SHBG driver rather than reflexively raising testosterone dose.

The Endocrine Society recommends measuring both total T and SHBG simultaneously whenever evaluating androgen status, since "calculated free testosterone provides a better estimate of biologically active testosterone than total testosterone alone." Bhasin S, et al.

Summary of Rate-of-Change Decision Points

The table below consolidates the clinical decision thresholds described throughout this article.

| Scenario | BioT Rate of Change | Recommended Action | |---|---|---| | Untreated man, age 35 to 55 | Minus 0.1% to minus 0.15%/month | Annual monitoring | | Untreated man, age 55 plus | Minus 0.2% to minus 0.25%/month | Annual monitoring; consider SHBG check | | Accelerated unexplained decline | Faster than minus 0.5%/month | Investigate SHBG, thyroid, hepatic, opioid causes | | On TRT, first titration | Plus 1% to plus 2%/month | Expected; confirm at 3-month trough | | On TRT, over-replacement signal | Greater than plus 3%/month | Reduce dose; check hematocrit immediately | | Postmenopausal woman, symptomatic | Below minus 1%/month | Evaluate for testosterone therapy candidacy per Global Consensus |